USPTO serial 99603537
WITHZETA
Reviewed by CopyMark Law Group
Status 653
- Filing date
- Status date
- Registration date
- —
- Examiner
- RINKER, ANTHONY MICHAEL
- Law office
- TMO LAW OFFICE 119
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with WITHZETA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nigamnarayan Acharya
1920 McKinney Avenue 7th FloorDALLAS, TX 75201United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable computer software for providing computational models and simulations for identifying, evaluating, and prioritizing therapeutic targets, drug candidates, and combination therapies; downloadable artificial intelligence software platform featuring software for hypothesis generation, in silico experimentation, and data-driven scientific discovery in the field of oncology; downloadable computer software for designing, modeling, and optimizing clinical trial concepts and research protocols for research of medical therapies; downloadable computer software for predictive analytics, biomarker discovery, drug response modeling, and validation of scientific hypotheses in the field of oncology | ACTIVE | Jan 20, 2026 |
| 042 | Providing temporary use of a non-downloadable artificial intelligence software platform featuring software for {specify the function of the software} in the fields of scientific and biomedical research; providing an online software-as-a-service (SaaS) platform featuring artificial intelligence and machine-learning software for analyzing biological, genomic, proteomic, clinical, and pharmacological data; scientific research services using artificial intelligence in the field of oncology and rare diseases; providing temporary use of a non-downloadable artificial intelligence software platform featuring software for computational models and simulations for identifying, evaluating, and prioritizing therapeutic targets, drug candidates, and combination therapies in the field of oncology; Providing on-line non downloadable software using artificial intelligence (AI) for hypothesis generation, in silico experimentation, and data-driven scientific research in the fields of {specify}; providing an online software-as-a-service (SaaS) platform featuring softwarefor designing, modeling, and optimizing clinical trial concepts and research protocols for investigational medical therapies; providing an online software-as-a-service (SaaS) platform featuring software for predictive analytics, biomarker discovery, drug response modeling, and validation of scientific hypotheses in the fields of oncology; providing scientific data analysis, visualization, and interpretation services using artificial intelligence in the field of oncology;providing an online software-as-a-service (SaaS) platform featuring software for accelerating biomedical research and development of therapeutic drugs through computational model simulations; Providing medical and scientific research information in the field of oncology and rare diseases; providing information and analysis relating to biomedical research and drug discovery, not for the purpose of diagnosis or treatment. | ACTIVE | Jan 20, 2026 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 23, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 23, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 23, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 18, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 18, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 18, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 26, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 26, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 17, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| May 7, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 20, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 20, 2026 | NWAP | NEW APPLICATION ENTERED | — |